EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access

Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality

Manish Manrai, Aditya V Pachisia, Atul A Jha, Rajat Shukla, Vivek Hande, Sandeep Thareja

World Journal of Virology · 2026

DOI: 10.5501/wjv.121081 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Virology, 2026. Verfasst von Manish Manrai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Command Hospital, Lucknow 226002, Uttar Pradesh, India. manishmanrai75@gmail.com. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with inflammatory bowel disease (IBD) have a 1.3-2.0 times higher risk of developing herpes zoster (HZ) compared to the general population, mainly due to immunosuppressive treatments. The risk is greatest with Janus kinase inhibitors, combination therapies, and high-dose corticosteroids, especially in younger patients with Crohn’s disease. The recombinant zoster vaccine (RZV, Shingrix) provides high efficacy, with 65%-90% protection against HZ and a significant decrease in postherpetic neuralgia, along with a safety profile that does not increase IBD flares, even during immunosuppression. Guidelines from the American College of Gastroenterology, the European Crohn’s and Colitis Organisation, and the Advisory Committee on Immunisation Practices strongly advise RZV for all IBD patients aged 50 and above, as well as those aged 19 and over undergoing immunomodulatory therapy. Real-world evidence supports consistent benefits across different age groups, treatments, and ethnic backgrounds. Nonetheless, there are notable implementation gaps, particularly in resource-poor Asian regions such as India, due to cost, awareness, and access constraints. Adopting a risk-gradient approach that targets high-risk individuals helps optimise resource allocation. RZV is a safe, effective, and cost-efficient method to decrease HZ-associated morbidity in IBD patients. Integrating vaccination proactively into routine IBD management is crucial to close the gap between current evidence and clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseHerpes zosterImmunosuppressionInflammatory bowel diseaseJanus kinase inhibitorsPostherpetic neuralgiaRecombinant zoster vaccineShinglesUlcerative colitisVaccination

Autor:innen und Institutionen

  • Department of Gastroenterology, Command Hospital, Lucknow 226002, Uttar Pradesh, India. manishmanrai75@gmail.com.
  • Department of Gastroenterology, Command Hospital, Bangalore 560007, Karnātaka, India.
  • Department of Gastroenterology, Command Hospital, Lucknow 226002, Uttar Pradesh, India.
  • Department of Gastroenterology, Army Hospital Research and Referral, Delhi 110001, India.

Zitieren

APA

Manrai, M., Pachisia, A. V., Jha, A. A., Shukla, R., Hande, V., & Thareja, S. (2026). Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality. World Journal of Virology. https://doi.org/10.5501/wjv.121081

Vancouver

Manrai M, Pachisia AV, Jha AA, Shukla R, Hande V, Thareja S. Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality. World Journal of Virology. 2026. doi:10.5501/wjv.121081

BibTeX
@article{Manrai2026,
  author = {Manrai, Manish and Pachisia, Aditya V and Jha, Atul A and Shukla, Rajat and Hande, Vivek and Thareja, Sandeep},
  title = {Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality},
  journal = {World Journal of Virology},
  year = {2026},
  doi = {10.5501/wjv.121081}
}
Kostenlos starten →